晚期肾细胞癌患者报告结局的测量与报告:一项系统文献综述
该系统综述检索四个在线数据库(2016-2021年)及近期会议摘要(2019-2021年),共纳入33项临床研究。研究识别出19种不同的患者报告结局测量工具(PROMs),仅42%的研究报告了患者报告结局(PRO)的终点层级,且时间点、最小重要差异和统计分析方法报告高度异质。
要点
- 晚期肾细胞癌研究中共识别出19种不同的PROMs,包括3种肾癌特异性量表、2种癌症特异性量表、2种通用量表和12种症状特异性量表。
- 仅42%的研究报告了PRO评估的终点层级,其中1项研究将PRO作为主要终点。
- PRO评估的时间点、最小重要差异和统计分析方法报告高度异质。
核心结论
- 晚期/转移性肾细胞癌临床研究中纳入了多种多样的PROMs,PRO评估的预设分析通常未明确说明,分析方法和报告方式存在差异。
- 提高研究间的一致性将更好地为监管、市场准入、报销和临床决策提供信息,从而改善患者照护。
研究设计与样本
- 系统文献综述,遵循PRISMA指南,检索四个在线数据库(2016-2021年)和近期会议摘要(2019-2021年),共识别2616篇文章,最终纳入33项临床研究。
主要发现
- 在33项纳入的临床研究中,共识别出19种不同的PROMs:3种肾癌特异性量表、2种癌症特异性量表、2种通用量表和12种症状特异性量表。
- 42%的研究报告了PRO评估的终点层级,其中1项研究将PRO作为主要终点。
- 时间点、最小重要差异和统计分析方法的报告高度异质。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In the oncology setting, patient-reported outcome measures (PROMs) provide important data that help to ensure patient-relevant endpoints are captured and reported. Use of this information for treatment decision-making by clinicians and patients in real-world settings is facilitated by consistent and transparent reporting of trial methods. OBJECTIVE: To identify and compare PROMs used in advanced renal cell carcinoma (RCC) trials in terms of the rationale for the choice of measure, endpoint hierarchy (primary, secondary, exploratory), assessment time points, statistical methods, and statistical metrics for interpretation. EVIDENCE ACQUISITION: A systematic literature review via searches of four online databases (2016-2021) and recent conference abstracts (2019-2021) identified 2616 articles, of which 33 were included in the review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. EVIDENCE SYNTHESIS: Among the 33 clinical studies included, 19 different PROMs were identified: three kidney cancer-specific scales, two cancer-specific scales, two generic scales, and 12 symptom-specific scales. The endpoint hierarchy for patient reported outcome (PRO) assessment was reported in 42% of the studies; one study included PROs as a primary endpoint. Reporting of time points, minimal important differences, and statistical analyses was highly heterogeneous. CONCLUSIONS: A diverse range of PROMs have been included in clinical studies for patients with advanced/metastatic RCC. Prespecified analyses for PRO assessments were generally not stated, while analytical methods and reporting varied. An improvement in alignment across studies would better inform regulatory, market-access, reimbursement, and clinical decision-making to improve patient care. PATIENT SUMMARY: We reviewed how the impact of cancer therapies on health outcomes from the patient's point of view is being measured in clinical trials for kidney cancer. The techniques and reporting varied across trials. Standardisation of how these data are captured and reported may improve care and decision-making for patients with kidney cancer.
引用
- Motzer RJ, Rane PP, Saretsky TL, et al. Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review. Eur Urol. 2023. PMID: 37550153. doi:10.1016/j.eururo.2023.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。